Nanomedical Diagnostics launches
Nanomed co-founders Ross Bundy and Dr. Brett Goldsmith have launched Nanomedical Diagnostics, a San Diego-based biotech company developing and commercializing bioelectronics for use in research and diagnostics. Nanomed’s first product, AGILE Research, a label-free, quantitative, low-cost biosensor for small molecule and protein analysis, is entering beta testing this fall and planned for commercial release in early 2016.
AGILE Research is based on graphene biological field effect transistor (BioFET) technology, a field CTO Dr. Goldsmith pioneered over the past decade across both his academic and professional career. One of the few people in the world with the combined expertise in biology and nanotechnology needed to develop graphene as a viable bioelectronic device, Dr. Goldsmith teamed with his childhood friend Ross Bundy to start Nanomed at the end of 2013.
Nanomed’s current focus is finalizing AGILE Research product design and will be evaluating its performance with the Centers for Disease Control and Prevention (CDC) and Stanford University. The CDC and Nanomedical Diagnostics are entering into a cooperative R&D agreement to evaluate direct electronic detection of Borrelia burgdorferi antigens for a new Lyme disease diagnostic system. Lyme disease research also is a focal point in the Stanford beta test.